Non-Hormonal Alternatives to HRT

Educational only. Not medical advice. Non-hormonal treatments have their own side effects, contraindications, and interactions. Discuss options with your clinician before starting.

Not every woman can take HRT. Some have contraindications (hormone-sensitive breast cancer, active VTE, certain other conditions). Some choose not to for personal reasons. Some are still deciding and want to know what else exists.

The good news: non-hormonal options have expanded significantly. The bad news: nothing matches HRT’s efficacy for vasomotor symptoms. The best non-hormonal treatments reduce hot flash frequency by 40 to 65%. HRT reduces it by 75 to 95%. That gap matters, and being honest about it helps women make informed choices rather than being disappointed by unrealistic expectations.

• Fezolinetant (Veozah) is the first non-hormonal medication designed specifically for menopausal hot flashes - approved 2023, reduces hot flashes by approximately 60%
• SSRIs/SNRIs reduce hot flashes by 40 to 65% in trials. Paroxetine low-dose (Brisdelle) is the only SSRI FDA-approved specifically for vasomotor symptoms
• Gabapentin is particularly useful when hot flashes are worst at night - its sedative effect provides dual benefit for sleep
• CBT for menopause (CBT-M) has RCT evidence for reducing hot flash bother and improving sleep, mood, and quality of life
• No non-hormonal option addresses vaginal atrophy - vaginal estrogen remains the most effective treatment for GSM and is considered low-risk even for many women who cannot use systemic HRT
• “Natural” supplements (black cohosh, soy, evening primrose) have weak evidence at best - see the supplements guide

Fezolinetant (Veozah). NK3 receptor antagonist. FDA-approved 2023 specifically for moderate-to-severe vasomotor symptoms. The first medication designed to target the neural pathway that drives hot flashes. Reduces hot flash frequency by approximately 60% in trials. Taken orally once daily. Main side effects: abdominal pain, diarrhea, insomnia, and hepatic effects (liver function monitoring required — LFTs at baseline, then monthly for the first 3 months, and at months 6 and 9. If LFTs become significantly elevated or signs of liver injury develop (unexplained fatigue, nausea, right upper abdominal pain, jaundice, dark urine), fezolinetant should be discontinued and a clinician contacted promptly (boxed warning for hepatotoxicity added December 2024). FDA boxed warning for hepatotoxicity). Contraindicated in patients with cirrhosis (any severity), severe renal impairment, end-stage renal disease, and with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin). Caution is also warranted with moderate CYP1A2 inhibitors — confirm all drug interactions with a pharmacist or prescriber before starting. Cost: approximately $485 to 690 per month; insurance coverage variable. This is the most significant non-hormonal development in menopause treatment in decades.

Paroxetine low-dose (Brisdelle). 7.5 mg daily - lower than antidepressant doses. The only SSRI FDA-approved for vasomotor symptoms. Reduces hot flash frequency by approximately 40 to 65%. Side effects at this dose are generally mild (nausea, headache, fatigue). Does not require the 4 to 6 week onset of antidepressant dose SSRIs. Some effect within 1 to 2 weeks. Important: paroxetine is a potent CYP2D6 inhibitor and should NOT be used by women taking tamoxifen (it reduces tamoxifen’s effectiveness).

Other SSRIs/SNRIs used off-label. Venlafaxine (37.5 to 150 mg daily) and desvenlafaxine (100 to 150 mg daily) have the most evidence after paroxetine. Escitalopram and citalopram also have data. These are off-label for vasomotor symptoms but commonly prescribed. They provide dual benefit for women who also have mood symptoms.

Gabapentin. 300 to 900 mg daily, typically at bedtime. Reduces hot flashes by approximately 45 to 55%. Particularly useful when hot flashes are worst at night because the sedative effect helps sleep. Side effects: drowsiness, dizziness, peripheral edema. Often used at bedtime as a “two birds” approach for nocturnal hot flashes and insomnia.

Clonidine. Alpha-2 adrenergic agonist. Modest efficacy for hot flashes (approximately 30 to 40% reduction). Available as oral or transdermal patch. Side effects: dry mouth, drowsiness, hypotension. Generally considered a second- or third-line option.

Oxybutynin. Anticholinergic typically used for overactive bladder. Has shown surprisingly good efficacy for hot flashes in recent trials (approximately 60 to 70% reduction in some studies). Available as extended-release oral or transdermal patch. Side effects: dry mouth, constipation, cognitive effects (use with caution in older adults). An emerging option.

CBT for menopause (CBT-M). Structured psychological intervention adapted specifically for menopausal symptoms. RCT evidence shows significant reduction in hot flash bother (not necessarily frequency, but the distress and interference they cause), insomnia, mood symptoms, and overall quality of life. Typically 4 to 6 sessions. Not widely available but growing. Can be delivered in person, in groups, or online. No side effects. Complements any other treatment.

Regular exercise. Moderate evidence for reducing hot flash frequency and severity. Strongest evidence for cardiovascular benefit, mood improvement, weight management, and bone health during menopause. Does not replace HRT for severe vasomotor symptoms but is foundational for overall menopausal health.

Weight management. Obesity is associated with more severe hot flashes. Weight loss of 10%+ has been shown to reduce vasomotor symptoms in some studies. The mechanism: adipose tissue is metabolically active and affects thermoregulation.

No non-hormonal option effectively treats vaginal atrophy (GSM). If vaginal dryness, painful intercourse, or urinary symptoms are present, vaginal estrogen is the most effective treatment and is considered low-risk even for many women who cannot use systemic HRT (including some breast cancer survivors - discuss with oncology). Over-the-counter moisturizers and lubricants provide symptomatic relief but do not reverse tissue changes.

No non-hormonal option provides the bone-protective benefits of estrogen. Women with osteoporosis risk who cannot take HRT should discuss bisphosphonates or denosumab with their clinician.

Combining Non-Hormonal Approaches

No single non-hormonal option matches HRT’s efficacy. But combining two or three can narrow the gap meaningfully.

The most evidence-supported combinations: SSRI/SNRI plus gabapentin at bedtime (vasomotor symptom reduction from the SSRI plus sleep benefit from gabapentin’s sedative effect). SSRI/SNRI plus CBT for menopause (pharmacological symptom reduction plus behavioral strategies for coping and sleep). Fezolinetant plus CBT (targeted vasomotor reduction plus behavioral support).

For women who cannot take any hormones (including vaginal estrogen), the maximum non-hormonal approach looks like: fezolinetant or SSRI/SNRI for vasomotor symptoms, gabapentin at bedtime for nocturnal symptoms and sleep, CBT-M for coping and quality of life, vaginal moisturizer (Replens) 3x/week plus lubricant for sexual activity, resistance training for bone and metabolic protection, and bisphosphonate if bone density warrants pharmacological intervention.

This combination requires multiple prescriptions, lifestyle commitment, and coordination - which is partly why HRT, as a single intervention addressing most symptoms simultaneously, is the more efficient approach when it is an option. But for women for whom HRT is not an option, this multi-modal strategy provides meaningful relief rather than silent suffering.

Fezolinetant vs SSRIs: How To Choose

If vasomotor symptoms are the primary concern and mood is stable: fezolinetant targets the mechanism more directly with a cleaner side effect profile. If mood symptoms are significant alongside hot flashes: an SSRI/SNRI addresses both. If you are on tamoxifen: fezolinetant or venlafaxine/desvenlafaxine (avoid paroxetine and fluoxetine due to CYP2D6 interaction). If cost is the primary concern: generic SSRIs at $4 to 15 per month versus fezolinetant at $485 to 690 per month.

• Given my contraindications to HRT, which non-hormonal option has the best evidence for my primary symptoms?
• Is fezolinetant (Veozah) appropriate for me, and would my insurance cover it?
• Can I use low-dose vaginal estrogen even though I cannot use systemic HRT?
• Would combining two non-hormonal approaches (e.g., SSRI + gabapentin) provide better relief than either alone?
• Is there a CBT-M program available in my area or online?